Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Grugni G, Guzzaloni G, Morabito F

Journal of endocrinological investigation1 May 2001Cited by 12 (Europe PMC)

PMID11407654DOI10.1007/bf03343871PepBankPUB-11407654

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialActivity measurement
In patients with Prader-Willi syndrome, peak GH after GHRP‑6 was lower than in patients with essential obesity.
In plain wordsIn Prader-Willi syndrome, peak growth hormone after GHRP‑6 was lower than in essential obesity.
Peptide
GHRP-6
Outcome
DecreasePeak GH in PWS versus obesity
Study
n = 31
Comparator
essential obesity
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
Peak GH (GHp)
11.4 mcg/l
PWS patients after GHRP-6, mean +/- 2.0
Peak GH (GHp)
25.7 mcg/l
essential obesity patients after GHRP-6, mean +/- 3.2
Source sentences
Summary
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765401
02HumanNon-randomized trialActivity measurement
In patients with Prader-Willi syndrome, GH AUC after GHRP‑6 was lower than in patients with essential obesity.
In plain wordsIn Prader-Willi syndrome, total growth hormone response to GHRP‑6 was lower than in essential obesity.
Peptide
GHRP-6
Outcome
DecreaseGH AUC in PWS versus obesity
Study
n = 31
Comparator
essential obesity
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
GH AUC
588 mcg/l/h
PWS patients after GHRP-6, mean +/- 113
GH AUC
1833 mcg/l/h
essential obesity patients after GHRP-6, mean +/- 305
Source sentences
Summary
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765402
03HumanNon-randomized trialActivity measurement
In patients with Prader-Willi syndrome, GH incremental AUC after GHRP‑6 was lower than in patients with essential obesity.
In plain wordsIn Prader-Willi syndrome, the growth hormone increase after GHRP‑6 was lower than in essential obesity.
Peptide
GHRP-6
Outcome
DecreaseGH incremental AUC in PWS versus obesity
Study
n = 31
Comparator
essential obesity
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
GH net incremental AUC (nAUC)
483 mcg/l/h
PWS patients after GHRP-6, mean +/- 108
GH net incremental AUC (nAUC)
1640 mcg/l/h
essential obesity patients after GHRP-6, mean +/- 263
Source sentences
Summary
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765403
04HumanNon-randomized trialActivity measurement
In patients with Prader-Willi syndrome, peak GH after GHRP‑6 was lower than in short normal children.
In plain wordsIn Prader-Willi syndrome, peak growth hormone after GHRP‑6 was lower than in short normal children.
Peptide
GHRP-6
Outcome
DecreasePeak GH in PWS versus short normal children
Study
n = 24
Comparator
short normal children
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
Peak GH (GHp)
11.4 mcg/l
PWS patients after GHRP-6, mean +/- 2.0
Peak GH (GHp)
39.1 mcg/l
short normal children after GHRP-6, mean +/- 3.1
Source sentences
Summary
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB
2 context sentences(design, population, supporting numbers)
Summary · context
or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005.
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765404
05HumanNon-randomized trialActivity measurement
In patients with Prader-Willi syndrome, GH AUC after GHRP‑6 was lower than in short normal children.
In plain wordsIn Prader-Willi syndrome, total growth hormone response to GHRP‑6 was lower than in short normal children.
Peptide
GHRP-6
Outcome
DecreaseGH AUC in PWS versus short normal children
Study
n = 24
Comparator
short normal children
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
GH AUC
588 mcg/l/h
PWS patients after GHRP-6, mean +/- 113
GH AUC
2792 mcg/l/h
short normal children after GHRP-6, mean +/- 158
Source sentences
Summary
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB
2 context sentences(design, population, supporting numbers)
Summary · context
or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005.
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765405
06HumanNon-randomized trialActivity measurement
In patients with Prader-Willi syndrome, GH incremental AUC after GHRP‑6 was lower than in short normal children.
In plain wordsIn Prader-Willi syndrome, the growth hormone increase after GHRP‑6 was lower than in short normal children.
Peptide
GHRP-6
Outcome
DecreaseGH incremental AUC in PWS versus short normal children
Study
n = 24
Comparator
short normal children
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
GH net incremental AUC (nAUC)
483 mcg/l/h
PWS patients after GHRP-6, mean +/- 108
GH net incremental AUC (nAUC)
2705 mcg/l/h
short normal children after GHRP-6, mean +/- 165
Source sentences
Summary
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB
2 context sentences(design, population, supporting numbers)
Summary · context
or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005.
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765406
07HumanNon-randomized trialActivity measurement
In Prader-Willi syndrome, GH levels after GHRP‑6 did not differ from levels after GHRH plus PD.
In plain wordsIn Prader-Willi syndrome, GHRP‑6 and GHRH plus PD produced similar growth hormone levels.
Peptide
GHRP-6
Outcome
No significant changeGH response versus GHRH plus PD in PWS
Study
n = 16
Comparator
GHRH plus PD
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
Peak GH (GHp)
11.4 mcg/l
GHRP-6 test in PWS patients, mean +/- 2.0
Peak GH (GHp)
7.3 mcg/l
GHRH+PD test in PWS patients, mean +/- 1.8
GH AUC
588 mcg/l/h
GHRP-6 test in PWS patients, mean +/- 113
GH AUC
486 mcg/l/h
GHRH+PD test in PWS patients, mean +/- 122
GH net incremental AUC (nAUC)
483 mcg/l/h
GHRP-6 test in PWS patients, mean +/- 108
GH net incremental AUC (nAUC)
371 mcg/l/h
GHRH+PD test in PWS patients, mean +/- 250
Source sentences
Summary
Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001.
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765407
08HumanNon-randomized trialActivity measurement
In patients with essential obesity, GH responses after GHRP‑6 were greater than after GHRH plus PD.
In plain wordsIn patients with obesity, GHRP‑6 produced greater growth hormone responses than GHRH plus PD.
Peptide
GHRP-6
Outcome
IncreaseGH response versus GHRH plus PD in obesity
Study
n = 15
Comparator
GHRH plus PD
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
Peak GH (GHp)
25.7 mcg/l
GHRP-6 test in essential obesity patients, mean +/- 3.2
Peak GH (GHp)
15.1 mcg/l
GHRH+PD test in essential obesity patients, mean +/- 2.4
GH AUC
1833 mcg/l/h
GHRP-6 test in essential obesity patients, mean +/- 305
GH AUC
1249 mcg/l/h
GHRH+PD test in essential obesity patients, mean +/- 248
GH net incremental AUC (nAUC)
1640 mcg/l/h
GHRP-6 test in essential obesity patients, mean +/- 263
GH net incremental AUC (nAUC)
918 mcg/l/h
GHRH+PD test in essential obesity patients, mean +/- 230
Source sentences
Summary
Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD.
3 context sentences(design, population, supporting numbers)
Summary · context
In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001.
Summary · context
GHRH+PD: GHp: 15.1+/-2.4, p<0.009; AUC: 1249+/-248, p<0.003; nAUC: 918+/-230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005.
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765408
09HumanNon-randomized trialActivity measurement
In short normal children, GH responses after GHRP‑6 were greater than after GHRH plus PD.
In plain wordsIn short normal children, GHRP‑6 produced greater growth hormone responses than GHRH plus PD.
Peptide
GHRP-6
Outcome
IncreaseGH response versus GHRH plus PD in short normal children
Study
n = 8
Comparator
GHRH plus PD
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · ivAs given in this study (human).
Measurements
Peak GH (GHp)
39.1 mcg/l
GHRP-6 test in short normal children, mean +/- 3.1
Peak GH (GHp)
27.5 mcg/l
GHRH+PD test in short normal children, mean +/- 3.7
GH AUC
2792 mcg/l/h
GHRP-6 test in short normal children, mean +/- 158
GH AUC
1873 mcg/l/h
GHRH+PD test in short normal children, mean +/- 251
GH net incremental AUC (nAUC)
2705 mcg/l/h
GHRP-6 test in short normal children, mean +/- 165
GH net incremental AUC (nAUC)
1692 mcg/l/h
GHRH+PD test in short normal children, mean +/- 219
Source sentences
Summary
Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD.
3 context sentences(design, population, supporting numbers)
Summary · context
GHRH+PD: GHp: 15.1+/-2.4, p<0.009; AUC: 1249+/-248, p<0.003; nAUC: 918+/-230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005.
Summary · context
GHRH+PD: GHp: 27.5+/-3.7, p<0.0001; AUC: 1873+/-251, p<0.0001; nAUC: 1692+/-219, p<0.0005).
Summary · context
Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, i…
Report a problemFND-1140765409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.